New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
07:25 EDTAGN, SHPG, VRX, JAZZ, ALKSAllergan approached Shire about potential takeover months ago, Reuters says
Allergan (AGN) reportedly approached Shire (SHPG) several months ago about a possible takeover, Reuters reports, though initial conversations never turned into more serious discussions. Since then, Allergan has received an unsolicited $47B offer from Valeant (VRX) and Pershing Square. It is unclear whether Allergan will look to revive talks with Shire or pursue another acquisition target like Jazz (JAZZ) or Alkermes (ALKS). Reference Link
News For AGN;SHPG;VRX;JAZZ;ALKS From The Last 14 Days
Check below for free stories on AGN;SHPG;VRX;JAZZ;ALKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 27, 2014
17:49 EDTSHPGGSK, Shire rumored to be interested in Tekmira, Daily Mail says
GlaxoSmithKline (GSK) and Shire (SHPG) are rumored to be interested in a bid for Tekmira (TKMR), reports Daily Mail. Tekmira could be a value to potential suitors, capitalized at approximately GBP 400M and the company could cost over GBP 1B in a takeover, Daily Mail adds. Reference Link
13:33 EDTAGN, VRXValeant, Pershing suit against Allergan expedited, WSJ says
After a hearing on Wednesday morning in Delaware Chancery Court, a judge has expedited a lawsuit from Valeant (VRX) and Pershing Square's William Ackman against Allergan (AGN), says the Wall Street Journal. Last week Valeant and Ackman sued Allergan to quickly schedule a special meeting to decide on the fate of Allergan's board members, added the Wall Street Journal. Reference Link
August 26, 2014
20:04 EDTAGN, VRXAllergan requests block to Ackman, Valeant votes, announces Special Meeting date
Subscribe for More Information
16:45 EDTVRX, AGNAllergan schedules special meeting on takeover for December 18, WSJ says
Subscribe for More Information
07:05 EDTALKSAlkermes initiates Phase 1 clinical study of ALKS 7106 for treatment of pain
Subscribe for More Information
August 25, 2014
12:19 EDTJAZZJazz Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information
07:01 EDTALKSAlkermes submits NDA to FDA for aripiprazole lauroxil
Subscribe for More Information
August 22, 2014
19:02 EDTAGN, VRXAllergan confirms Pershing written request, board views Valeant offer inadequate
Subscribe for More Information
18:33 EDTAGN, VRXPershing Square submits requisite requests from Allergan holders to call meeting
Subscribe for More Information
09:33 EDTAGN, VRXValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTAGN, VRXJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTAGN, VRXJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Subscribe for More Information
August 20, 2014
17:59 EDTVRX, AGNAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTAGN, VRXAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTVRX, AGNAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTVRX, JAZZ, AGNAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTVRX, AGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use